Hellstern Peter, Solheim Bjarte G
Institute of Hemostaseology and Transfusion Medicine, Academic City Hospital Ludwigshafen, Ludwigshafen, Germany.
Transfus Med Hemother. 2011;38(1):65-70. doi: 10.1159/000323552. Epub 2011 Jan 17.
The solvent/detergent (SD) process used for plasma can safely inactivate all lipid-enveloped viruses. The introduction of a specific prion-binding ligand gel in combination with SD treatment, time-reduced from 4 to 1-1.5 h, still ensures efficient virus kill, reduces abnormal prion protein by >5 log steps, and preserves levels of plasmin inhibitor at close to the reference range. Infections with known non-enveloped viruses such as HAV or parvovirus B19 are prevented by ensuring low virus loads in the starting plasma units, dilution through pooling of single plasma units, and neutralization of immune antibodies already present in the initial plasma pools. The major advantages of SD plasma over fresh frozen plasma and the other pathogen-inactivated plasmas are its extreme safety with respect to transfusion-related acute lung injury and the significantly lower likelihood of provoking allergic reactions. Both advantages are best interpreted as results of the dilution effect of pooling. No fewer than 18 clinical studies covering all indications for plasma, and extensive clinical experience have shown that reduced levels of coagulation factors and inhibitors as a result of SD treatment do not impair significantly the clinical efficacy or tolerance of plasma. Properly standardized clotting factor and inhibitor potencies and low batch-to-batch variations when compared with single-donor plasma units makes SD plasma more suitable for standardized treatment.
用于血浆的溶剂/去污剂(SD)工艺能够安全地灭活所有脂包膜病毒。引入一种特定的朊病毒结合配体凝胶并结合SD处理,可将时间从4小时缩短至1 - 1.5小时,仍能确保有效杀灭病毒,将异常朊病毒蛋白减少超过5个对数级,并使纤溶酶抑制剂水平维持在接近参考范围。通过确保起始血浆单位中的病毒载量较低、通过合并单个血浆单位进行稀释以及中和初始血浆库中已存在的免疫抗体,可预防已知的非包膜病毒如甲型肝炎病毒或细小病毒B19的感染。与新鲜冰冻血浆和其他病原体灭活血浆相比,SD血浆的主要优势在于其在输血相关急性肺损伤方面具有极高的安全性,以及引发过敏反应的可能性显著降低。这两个优势最好解释为合并稀释效应的结果。不少于18项涵盖血浆所有适应症的临床研究以及广泛的临床经验表明,SD处理导致的凝血因子和抑制剂水平降低并不会显著损害血浆的临床疗效或耐受性。与单供体血浆单位相比,适当标准化的凝血因子和抑制剂效价以及较低的批次间差异使SD血浆更适合标准化治疗。